Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation‐Positive Non‐Small Cell Lung Cancer: A Prospective, Single‐Arm, Phase II Study

LESSONS LEARNED. The findings of this prospective, single‐arm, phase II study showed that neoadjuvant erlotinib was well tolerated and might improve the radical resection rate in patients with stage IIIA‐N2 epidermal growth factor receptor mutation‐positive non‐small cell lung cancer (NSCLC). Erloti...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Xiong, Liwen, Li, Rong, Sun, Jiayuan, Lou, Yuqing, Zhang, Weiyan, Bai, Hao, Wang, Huiming, Shen, Jie, Jing, Bo, Shi, Chunlei, Zhong, Hua, Gu, Aiqin, Jiang, Liyan, Shi, Jianxing, Fang, Wentao, Zhao, Heng, Zhang, Jie, Wang, Junyuan, Ye, Junyi, Han, Baohui
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2018
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6369937/
https://ncbi.nlm.nih.gov/pubmed/30158288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0120
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados